Dominic A. Ritacco

Mr. Dominic A. Ritacco

Microbiology and Immunology, Columbia University Irving Medical Center, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
RBRaquel A Binder
Raquel A Binder
GFGavin F Fujimori
Gavin F Fujimori
CFCatherine S Forconi
Catherine S Forconi
GRGeorge W Reed
George W Reed
LSLeandro S Silva
Leandro S Silva
AMAnn M Moormann
Ann M Moormann
Background: Evaluating the performance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological assays and clearly articulating the utility of selected antigens, isotypes, and thresholds is crucial to understanding the prevalence of infection within selected communities. Methods: This cross-sectional study, implemented in 2020, screened PCR–confirmed coronavirus disease 2019 patients (n = 86), banked prepandemic and negative samples (n = 96), healthcare workers and family members (n = 552), and university employees (n = 327) for anti–SARS-CoV-2 receptor-binding domain, trimeric spike protein, and nucleocapsid protein immunoglobulin (Ig)G and IgA antibodies with a laboratory-developed enzyme-linked immunosorbent assay and tested how antigen, isotype and threshold choices affected the seroprevalence outcomes. The following threshold methods were evaluated: (i) mean + 3 standard deviations of the negative controls; (ii) 100% specificity for each antigen-isotype combination; and (iii) the maximal Youden index. Results: We found vastly different seroprevalence estimates depending on selected antigens and isotypes and the applied threshold method, ranging from 0.0% to 85.4%. Subsequently, we maximized specificity and reported a seroprevalence, based on more than one antigen, ranging from 9.3% to 25.9%. Conclusions: This study revealed the importance of evaluating serosurvey tools for antigen-, isotype-, and threshold-specific sensitivity and specificity, to interpret qualitative serosurvey outcomes reliably and consistently across studies.

24 February 2026 in Molecular Cell
Verified
Journal Article
Open access
Dominic A. RitaccoDominic A. Ritacco
Dominic A. Ritacco
HSHamna Shahnawaz
Hamna Shahnawaz
AOAntonia Oduguwa
Antonia Oduguwa
JHJacob Hawk
Jacob Hawk
BVBrianna Vizcaino
Brianna Vizcaino
Ryan Gilbert GaudetRyan Gilbert Gaudet
Ryan Gilbert Gaudet
Lysosomal damage is an endogenous danger signal, but its significance for innate immunity and the specific signaling pathways it engages remain unclear. Here, we uncover an immune-inducible pathway that connects lysosomal damage to mitochondrial DNA (mtDNA) efflux and type I IFN production. We find that transient lysosomal damage elicits sub-lethal mitochondrial outer membrane permeabilization (MOMP) via BAK/BAX macropores; however, the inner mitochondrial membrane (IMM) maintains a barrier against wholesale mtDNA release. Priming with type II IFN (IFN-γ) induced the antibacterial factor APOL3, which, upon sensing lysosomal damage, targets mitochondria undergoing MOMP to selectively permeabilize the IMM, enhance mtDNA release, and potentiate downstream cGAS signaling. Biochemical and cellular reconstitution revealed that, analogous to its bactericidal detergent-like mechanism, APOL3 permeabilized the IMM by solubilizing cardiolipin. Our findings illustrate how cells enlist an antibacterial protein to expedite the breakdown of endosymbiosis and facilitate a heightened response to injury and infection.

18 December 2024 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
BBBenoit Bestgen
Benoit Bestgen
SJSam Jones
Sam Jones
VTVandana Thathy
Vandana Thathy
AKAndrea Kuemmerle
Andrea Kuemmerle
CBCatalina Barcelo
Catalina Barcelo
SCStephan Chalon
Stephan Chalon
Novel antimalarials are needed to address emerging resistance to artemisinin and partner drugs. We did two trials to evaluate safety, tolerability, pharmacokinetics, and activity against blood stage Plasmodium falciparum for the drug candidate MMV533. A phase 1a first-in-human (FIH) trial was conducted at Nucleus Network (Melbourne, VIC, Australia). Part 1 was a double-blind, randomised, placebo-controlled, sequential ascending dose study and part 2 was an open-label, randomised, two-period crossover, pilot food effect study. A phase 1b, open-label, volunteer infection study (VIS) was conducted at Nucleus Network (Herston, QLD, Australia). Eligible participants were adults aged 18-55 years, with a bodyweight of at least 50 kg and BMI of 18-32 kg/m2 and participants in the VIS were malaria-naive. In part 1 of the FIH study, six cohorts of up to eight participants were randomly assigned (3:1) to a single oral MMV533 dose (5, 10, 20, 50, 100, and 160 mg) or placebo using an automated system, with study staff and participants masked to treatment allocation, and follow-up until day 28. In part 2, MMV533 30 mg was administered open-label to one cohort of nine participants assigned by simple randomisation (1:1) to the fasted-fed (n=4) or fed-fasted (n=5) groups. After a 21-day washout period, fed and fasted groups crossed over with follow-up until day 42. In the VIS, seven participants were assigned using simple randomisation (1:1:1) to three dosing groups of 20 mg (n=3), 35 mg (n=2), or 100 mg (n=2) after parasitaemia was detected, with follow-up until day 28. The primary outcomes were treatment emergent adverse events and relationship to MMV533 for the FIH study assessed in the safety population, and in the VIS primary outcomes were parasite reduction ratio over 48 h (log10PRR48), parasite clearance half-life (PCT1/2), and lag phase assessed in the pharmacodynamic population. MMV533 pharmacokinetics was a secondary outcome for both studies, evaluated in the pharmacokinetic population. The studies are registered with ClinicalTrials.gov, NCT04323306 and NCT05205941 (completed). The FIH study was conducted between July 31, 2020, and Sept 27, 2022, and the VIS between March 31 and Aug 9, 2022. 335 adults were assessed for eligibility, 71 enrolled, and 69 randomly assigned (53 in part 1 and nine in part 2 of the FIH study, and seven in the VIS). 32 (45%) of 71 participants were female and 39 (55%) were male. In part 1, 24 (63%) of 38 participants had an adverse event after MMV533 administration with no apparent relationship to dose versus six (50%) of 12 after placebo. Treatment-related adverse events were reported for four (11%) participants receiving MMV533 and one (8%) receiving placebo, with no relationship to dose. In part 2, adverse events were reported for three (38%) of eight participants when fasted and four (44%) of nine when fed, with no apparent influence of food. Time to maximum plasma concentration was 4·0-6·0 h, and apparent half-life was 103·8-127·2 h. After a high-fat meal, the geometric mean ratio (fed:fasted) of MMV533 AUC0-last was 112·0 (90% CI 89·6-140·0). In the VIS for MMV533 100 mg, log10PRR48 was 2·27 (1·99-2·56), PCT1/2 was 6·36 h (5·64-7·28), and lag phase was 2 h. An acceptable safety and tolerability profile, confirmed parasiticidal activity, and a long half-life support progression of MMV533 into clinical trials in patients with malaria as a component of new antimalarial combination therapies. MMV Medicines for Malaria Venture and Bill & Melinda Gates Foundation.

Verified
Journal Article
Open access
PDF file
POPeter O. Oluoch
Peter O. Oluoch
CFCatherine Forconi
Catherine Forconi
COCliff I. Oduor
Cliff I. Oduor
Dominic A. RitaccoDominic A. Ritacco
Dominic A. Ritacco
HAHoseah Miima Akala
Hoseah Miima Akala
AMAnn Moormann
Ann Moormann
The seroprevalence of Kaposi sarcoma-associated herpesvirus (KSHV) and the incidence of endemic Kaposi sarcoma (KS) overlap with regions of malaria endemicity in sub-Saharan Africa. Multiple studies have shown an increased risk of KSHV seroconversion in children from high malaria compared to low malaria regions; however, the impact of acute episodes of Plasmodium falciparum (P. falciparum) malaria on KSHV’s biphasic life cycle and lytic reactivation has not been determined. Here, we examined KSHV serological profiles and viral loads in 134 children with acute malaria and 221 healthy children from high malaria regions in Kisumu, as well as 77 healthy children from low malaria regions in Nandi. We assayed KSHV, Epstein–Barr virus (EBV), and P. falciparum malaria antibody responses in these three by multiplexed Luminex assay. We confirmed that KSHV seroprevalence was significantly associated with malaria endemicity (OR = 1.95, 1.18–3.24 95% CI, p = 0.01) with 71–77% seropositivity in high-malaria (Kisumu) compared to 28% in low-malaria (Nandi) regions. Furthermore, KSHV serological profiles during acute malaria episodes were distinct from age-matched non-malaria-infected children from the same region. Paired IgG levels also varied after malaria treatment, with significantly higher anti-ORF59 at day 0 but elevated ORF38, ORF73, and K8.1 at day 3. Acute malaria episodes is characterized by perturbation of KSHV latency in seropositive children, providing further evidence that malaria endemicity contributes to the observed increase in endemic KS incidence in sub-Saharan Africa.

6 November 2026 in Biology
Verified
Journal Article
Open access
PDF file
Ryan Gilbert GaudetRyan Gilbert Gaudet
Ryan Gilbert Gaudet
HSHamna Shahnawaz
Hamna Shahnawaz
Dominic A. RitaccoDominic A. Ritacco
Dominic A. Ritacco
Interferons (IFNs) are synonymous with mobilizing cell-intrinsic defenses against microbial infection through the induction of interferon-stimulated genes (ISGs). Omics-based profiling has revealed that ISGs also dominate the transcriptional signature of a wide range of human disease conditions, including cancer, autoimmune and autoinflammatory disorders, and even normal aging. The ubiquity of the IFN signature means it is often interpreted as a biomarker for upstream inflammation, with little consideration given to how persistent ISG induction might influence downstream cellular and tissue physiology. However, the identification of endogenous targets for a growing number of ISG-encoded effectors has broadened our appreciation for the function of these genes—both in terms of how self-defense is achieved but also for the potential implications emanating from their prolonged induction. The same host-directed mechanisms that provide broad antimicrobial protection can, depending on context, either preserve tissue homeostasis or contribute to chronic inflammation and tissue dysfunction. In this perspective, we revisit the longstanding question of IFN causality in disease and argue that ISGs should be viewed as active participants in pathogenesis rather than passive markers of inflammatory activity. By examining disease-specific ISG expression patterns and synthesizing emerging evidence for the endogenous functions of ISGs, many of which converge on mitochondrial regulation, we propose a framework in which the composition of an IFN signature associated with a diseased tissue plays a major role in dictating whether inflammation is resolved or perpetuated.